|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PTPRS |
Gene summary for PTPRS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PTPRS | Gene ID | 5802 |
| Gene name | protein tyrosine phosphatase receptor type S | |
| Gene Alias | PTPSIGMA | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q13332 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5802 | PTPRS | CCI_1 | Human | Cervix | CC | 2.34e-04 | 4.27e-01 | 0.528 |
| 5802 | PTPRS | CCI_3 | Human | Cervix | CC | 3.62e-12 | 6.63e-01 | 0.516 |
| 5802 | PTPRS | CCII_1 | Human | Cervix | CC | 4.23e-11 | 4.86e-01 | 0.3249 |
| 5802 | PTPRS | Tumor | Human | Cervix | CC | 2.43e-03 | 2.16e-01 | 0.1241 |
| 5802 | PTPRS | LZE7T | Human | Esophagus | ESCC | 2.07e-09 | 3.95e-01 | 0.0667 |
| 5802 | PTPRS | LZE22D1 | Human | Esophagus | HGIN | 5.14e-03 | 1.59e-01 | 0.0595 |
| 5802 | PTPRS | LZE24T | Human | Esophagus | ESCC | 1.09e-06 | 2.08e-01 | 0.0596 |
| 5802 | PTPRS | LZE21T | Human | Esophagus | ESCC | 1.57e-07 | 3.83e-01 | 0.0655 |
| 5802 | PTPRS | P1T-E | Human | Esophagus | ESCC | 2.65e-12 | 4.59e-01 | 0.0875 |
| 5802 | PTPRS | P2T-E | Human | Esophagus | ESCC | 1.30e-15 | 2.90e-01 | 0.1177 |
| 5802 | PTPRS | P4T-E | Human | Esophagus | ESCC | 3.18e-14 | 2.93e-01 | 0.1323 |
| 5802 | PTPRS | P5T-E | Human | Esophagus | ESCC | 1.96e-05 | 1.36e-01 | 0.1327 |
| 5802 | PTPRS | P8T-E | Human | Esophagus | ESCC | 2.51e-33 | 5.07e-01 | 0.0889 |
| 5802 | PTPRS | P9T-E | Human | Esophagus | ESCC | 1.69e-18 | 3.52e-01 | 0.1131 |
| 5802 | PTPRS | P10T-E | Human | Esophagus | ESCC | 2.08e-40 | 7.08e-01 | 0.116 |
| 5802 | PTPRS | P11T-E | Human | Esophagus | ESCC | 9.92e-21 | 6.26e-01 | 0.1426 |
| 5802 | PTPRS | P12T-E | Human | Esophagus | ESCC | 9.86e-34 | 6.04e-01 | 0.1122 |
| 5802 | PTPRS | P15T-E | Human | Esophagus | ESCC | 6.53e-23 | 4.49e-01 | 0.1149 |
| 5802 | PTPRS | P16T-E | Human | Esophagus | ESCC | 3.19e-23 | 3.47e-01 | 0.1153 |
| 5802 | PTPRS | P17T-E | Human | Esophagus | ESCC | 9.15e-12 | 3.97e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00905578 | Esophagus | ESCC | establishment of endothelial intestinal barrier | 10/8552 | 12/18723 | 8.94e-03 | 3.12e-02 | 10 |
| GO:00486791 | Esophagus | ESCC | regulation of axon regeneration | 20/8552 | 29/18723 | 9.66e-03 | 3.34e-02 | 20 |
| GO:004544610 | Esophagus | ESCC | endothelial cell differentiation | 67/8552 | 118/18723 | 9.86e-03 | 3.40e-02 | 67 |
| GO:004858810 | Esophagus | ESCC | developmental cell growth | 125/8552 | 234/18723 | 1.01e-02 | 3.46e-02 | 125 |
| GO:000315818 | Esophagus | ESCC | endothelium development | 76/8552 | 136/18723 | 1.05e-02 | 3.59e-02 | 76 |
| GO:190188810 | Esophagus | ESCC | regulation of cell junction assembly | 109/8552 | 204/18723 | 1.53e-02 | 4.96e-02 | 109 |
| GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
| GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
| GO:000647015 | Oral cavity | OSCC | protein dephosphorylation | 162/7305 | 281/18723 | 1.56e-10 | 4.56e-09 | 162 |
| GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
| GO:19021155 | Oral cavity | OSCC | regulation of organelle assembly | 109/7305 | 186/18723 | 4.54e-08 | 8.45e-07 | 109 |
| GO:003253519 | Oral cavity | OSCC | regulation of cellular component size | 201/7305 | 383/18723 | 4.80e-08 | 8.88e-07 | 201 |
| GO:00310999 | Oral cavity | OSCC | regeneration | 114/7305 | 198/18723 | 8.54e-08 | 1.50e-06 | 114 |
| GO:00459266 | Oral cavity | OSCC | negative regulation of growth | 135/7305 | 249/18723 | 7.29e-07 | 1.03e-05 | 135 |
| GO:00022214 | Oral cavity | OSCC | pattern recognition receptor signaling pathway | 95/7305 | 172/18723 | 1.11e-05 | 1.15e-04 | 95 |
| GO:000206419 | Oral cavity | OSCC | epithelial cell development | 116/7305 | 220/18723 | 2.34e-05 | 2.21e-04 | 116 |
| GO:00303084 | Oral cavity | OSCC | negative regulation of cell growth | 101/7305 | 188/18723 | 2.85e-05 | 2.63e-04 | 101 |
| GO:00326083 | Oral cavity | OSCC | interferon-beta production | 37/7305 | 56/18723 | 3.74e-05 | 3.32e-04 | 37 |
| GO:00326483 | Oral cavity | OSCC | regulation of interferon-beta production | 37/7305 | 56/18723 | 3.74e-05 | 3.32e-04 | 37 |
| GO:00507679 | Oral cavity | OSCC | regulation of neurogenesis | 179/7305 | 364/18723 | 4.49e-05 | 3.84e-04 | 179 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa045147 | Cervix | CC | Cell adhesion molecules | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
| hsa0451412 | Cervix | CC | Cell adhesion molecules | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PTPRS | SNV | Missense_Mutation | rs758242063 | c.554N>G | p.Lys185Arg | p.K185R | Q13332 | protein_coding | deleterious(0.04) | probably_damaging(0.986) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PTPRS | SNV | Missense_Mutation | rs749770933 | c.4976N>A | p.Arg1659His | p.R1659H | Q13332 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PTPRS | SNV | Missense_Mutation | rs771478606 | c.4886N>G | p.Asn1629Ser | p.N1629S | Q13332 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| PTPRS | insertion | In_Frame_Ins | novel | c.3570_3571insACCCAAGGCCAGGCTGGT | p.Arg1190_Leu1191insThrGlnGlyGlnAlaGly | p.R1190_L1191insTQGQAG | Q13332 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| PTPRS | insertion | In_Frame_Ins | novel | c.5580_5581insAGAGTC | p.Ile1860_Gly1861insArgVal | p.I1860_G1861insRV | Q13332 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| PTPRS | insertion | Frame_Shift_Ins | novel | c.5578_5579insGCCCCAAGCTTAGGCTGTCCCATCTGGGCTG | p.Ile1860SerfsTer16 | p.I1860Sfs*16 | Q13332 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| PTPRS | insertion | In_Frame_Ins | novel | c.3910_3911insAAG | p.Leu1304delinsGlnVal | p.L1304delinsQV | Q13332 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| PTPRS | insertion | Frame_Shift_Ins | novel | c.3909_3910insTTCAACTCAG | p.Leu1304PhefsTer13 | p.L1304Ffs*13 | Q13332 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| PTPRS | deletion | Frame_Shift_Del | novel | c.4210delN | p.Gln1404SerfsTer12 | p.Q1404Sfs*12 | Q13332 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| PTPRS | deletion | Frame_Shift_Del | novel | c.3363delN | p.Leu1122SerfsTer36 | p.L1122Sfs*36 | Q13332 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5802 | PTPRS | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE, CLINICALLY ACTIONABLE | inhibitor | 252827507 | ||
| 5802 | PTPRS | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE, CLINICALLY ACTIONABLE | Etidronic acid | |||
| 5802 | PTPRS | DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE, CLINICALLY ACTIONABLE | inhibitor | 381118819 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |